The Role of IL5 in Epithelial Cell Integrity

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell.

• (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and

• (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan.

Locations
United States
Maryland
Johns Hopkins Bayview Medical Center
RECRUITING
Baltimore
Johns Hopkins Hospital
RECRUITING
Baltimore
Contact Information
Primary
Jean Kim, MD PhD
jeankim@jhmi.edu
410-550-2644
Time Frame
Start Date: 2023-09-05
Estimated Completion Date: 2026-06
Participants
Target number of participants: 8
Treatments
Experimental: Mepolizumab treatment arm
Nasal epithelial cells will be exposed in vitro to mepolizumab in culture.
No_intervention: Control arm
Nasal epithelial cells will be exposed in vitro to media without mepolizumab in culture
Sponsors
Collaborators: GlaxoSmithKline
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials